Peroxisome proliferator-activated receptor-α activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: possible neuroprotective mechanisms.
- Authors
- Bhateja, Deepak Kumar; Dhull, Dinesh K; Gill, Aneet; Sidhu, Akramdeep; Sharma, Saurabh; Reddy, B V Krishna; Padi, Satyanarayana S V
- Year
- 2012
- Journal
- European journal of pharmacology
- PMID
- 22056833
- DOI
- 10.1016/j.ejphar.2011.10.029
Peroxisome proliferators activated receptor is regarded as potential therapeutic targets to control various neurodegenerative disorders. However, none of the study has elucidated its effect in the treatment of Huntington's disease. We explored whether peroxisome proliferators activated receptor-α agonist may attenuate various behavioral and biochemical alterations induced by systemic administration of 3-nitropropionic acid (3-NP), an accepted experimental animal model of Huntington's disease phenotype. Intraperitoneal administration of 3-NP (20mg/kg., i.p.) for 4days in rats produced hypolocomotion, muscle incoordination, and cognitive dysfunction. Daily treatment with fenofibrate (100 or 200mg/kg., p.o.), 30min prior to 3-NP administration for a total of 4days, significantly improved the 3-NP induced motor and cognitive impairment. Biochemical analysis revealed that systemic 3-NP administration significantly increased oxidative and nitrosative stress (increase lipid peroxidation, protein carbonyls and nitrite level), lactate dehydrogenase activity whereas, decreased the activities of catalase, superoxide dismutase, reduced glutathione, and succinate dehydrogenase. Fenofibrate treatment significantly attenuated oxidative damage, cytokines and improved mitochondrial complexes enzyme activity in brain. In the present study, MK886, a selective inhibitor of peroxisome proliferators activated receptor-α was employed to elucidate the beneficial effect through either receptor dependent or receptor independent neuroprotective mechanisms. Administration of MK886 (1mg/kg, i.p.) prior to fenofibrate (200mg/kg, p.o.) abolished the effect of fenofibrate. The results showed that receptor dependent neuroprotective effects of fenofibrate in 3-NP administered rats provide a new evidence for a role of PPAR-α activation in neuroprotection that is attributed by modulating oxidative stress and inflammation.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans. | 2015 | 25516156 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Artemisinin attenuates 3-nitropropionic acid-induced neurodegeneration via HMGB1/TLR4/NF-κB modulation in a rat model of huntington's disease. | Mustafa AM et al. | — | 2026 | → |
| Antioxidant and Anti-Inflammatory Defenses in Huntington's Disease: Roles of NRF2 and PGC-1α, and Therapeutic Strategies. | D'Egidio F et al. | — | 2025 | → |
| Are lipid-lowering drugs harmful to cognitive performance?: A Mendelian randomization study. | Han L et al. | — | 2025 | → |
| Oxidative Stress in Huntington's Disease. | Jiménez-Jiménez FJ et al. | — | 2025 | → |
| Role of peroxisome proliferator-activated receptors α and γ in mediating the beneficial effects of β-caryophyllene in a rat model of fragile X syndrome. | Rava A et al. | — | 2025 | → |
| Amelioration of propionic acid-induced autism-like behaviors in rats by fenofibrate: A focus on reduction of brain galectin-3 levels. | Erdogan MA et al. | — | 2024 | → |
| Neuroprotective effects of silymarin in 3-nitropropionic acid-induced neurotoxicity in male mice: improving behavioral deficits by attenuating oxidative stress and neuroinflammation. | Haddadi R et al. | — | 2024 | → |
| Saroglitazar, a PPAR α/γ agonist alleviates 3-Nitropropionic acid induced neurotoxicity in rats: Unveiling the underlying mechanisms. | Jakkamsetti MS et al. | — | 2024 | → |
| An Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington's Disease Model and Its Relevance to Drug Discovery and Development. | Upadhayay S et al. | — | 2023 | → |
| Anti-inflammatory role of fenofibrate in treating diseases. | Jin L et al. | — | 2023 | → |
| Mutant-Huntingtin Molecular Pathways Elucidate New Targets for Drug Repurposing. | Makeeva VS et al. | — | 2023 | → |
| Overview of the Role of Vanillin in Neurodegenerative Diseases and Neuropathophysiological Conditions. | Iannuzzi C et al. | — | 2023 | → |
| PPARα Signaling: A Candidate Target in Psychiatric Disorder Management. | Scheggi S et al. | — | 2022 | → |
| Small molecules to perform big roles: The search for Parkinson's and Huntington's disease therapeutics. | Pérez-Arancibia R et al. | — | 2022 | → |
| Fenofibrate ameliorates olanzapine's side effects without altering its central effect: emphasis on FGF-21-adiponectin axis. | Galal A et al. | — | 2021 | → |
| Adenylate cyclase activator forskolin alleviates intracerebroventricular propionic acid-induced mitochondrial dysfunction of autistic rats. | Mehan S et al. | — | 2020 | → |
| Benefits of Fenofibrate in prenatal valproic acid-induced autism spectrum disorder related phenotype in rats. | Mirza R et al. | — | 2019 | → |
| Neuroprotective potential of solanesol in intracerebroventricular propionic acid induced experimental model of autism: Insights from behavioral and biochemical evidence. | Sharma R et al. | — | 2019 | → |
| Peroxisomal Malfunction Caused by Mitochondrial Toxin 3-NP: Protective Role of Oxytocin. | Moslemi M et al. | — | 2019 | → |
| Nicotinamide reverses behavioral impairments and provides neuroprotection in 3-nitropropionic acid induced animal model ofHuntington's disease: implication of oxidative stress- poly(ADP- ribose) polymerase pathway. | Sidhu A et al. | — | 2018 | → |
| Palmitoylethanolamide prevents neuroinflammation, reduces astrogliosis and preserves recognition and spatial memory following induction of neonatal anoxia-ischemia. | Holubiec MI et al. | — | 2018 | → |
| PPARα/γ antagonists reverse the ameliorative effects of osthole on hepatic lipid metabolism and inflammatory response in steatohepatitic rats. | Zhao X et al. | — | 2018 | → |
| ADIOL protects against 3-NP-induced neurotoxicity in rats: Possible impact of its anti-oxidant, anti-inflammatory and anti-apoptotic actions. | Hanna DM et al. | — | 2015 | → |
| Beneficial effect of candesartan and lisinopril against haloperidol-induced tardive dyskinesia in rat. | Thakur KS et al. | — | 2015 | → |
| Perinatal asphyxia results in altered expression of the hippocampal acylethanolamide/endocannabinoid signaling system associated to memory impairments in postweaned rats. | Blanco E et al. | — | 2015 | → |
| Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans. | Blednov YA et al. | — | 2015 | → |
| PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats. | Zhang Y et al. | — | 2015 | → |
| Protective Effects of Aqueous Extract of Luehea divaricata against Behavioral and Oxidative Changes Induced by 3-Nitropropionic Acid in Rats. | Courtes AA et al. | — | 2015 | → |
| Involvement of peroxisome proliferator-activated receptor β/δ (PPAR β/δ) in BDNF signaling during aging and in Alzheimer disease: possible role of 4-hydroxynonenal (4-HNE). | Benedetti E et al. | — | 2014 | → |
| Neuroprotective activity of L-theanine on 3-nitropropionic acid-induced neurotoxicity in rat striatum. | Thangarajan S et al. | — | 2014 | → |
| Neuroprotective efficacy of a combination of fish oil and ferulic acid against 3-nitropropionic acid-induced oxidative stress and neurotoxicity in rats: behavioural and biochemical evidence. | K M DJ et al. | — | 2014 | → |
| Neuroprotective Potential of Peroxisome Proliferator Activated Receptor- α Agonist in Cognitive Impairment in Parkinson's Disease: Behavioral, Biochemical, and PBPK Profile. | Uppalapati D et al. | — | 2014 | → |
| Pharmacological benefit of I(1)-imidazoline receptors activation and nuclear factor kappa-B (NF-κB) modulation in experimental Huntington's disease. | Gupta S et al. | — | 2014 | → |
| Pharmacological benefits of agomelatine and vanillin in experimental model of Huntington's disease. | Gupta S et al. | — | 2014 | → |
| PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease. | Barbiero JK et al. | — | 2014 | → |
| Protective and antioxidant effects of PPARα in the ischemic retina. | Moran E et al. | — | 2014 | → |
| Puerarin ameliorates 3-nitropropionic acid-induced neurotoxicity in rats: possible neuromodulation and antioxidant mechanisms. | Mahdy HM et al. | — | 2014 | → |
| The anti-apoptotic and anti-inflammatory properties of puerarin attenuate 3-nitropropionic-acid induced neurotoxicity in rats. | Mahdy HM et al. | — | 2014 | → |
| The peroxisomal proliferator-activated receptor (PPAR) α agonist, fenofibrate, prevents fractionated whole-brain irradiation-induced cognitive impairment. | Greene-Schloesser D et al. | — | 2014 | → |
| Fenofibrate suppresses melanogenesis in B16-F10 melanoma cells via activation of the p38 mitogen-activated protein kinase pathway. | Huang YC et al. | — | 2013 | → |
| Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)--α and γ agonist against a rat model of oral dyskinesia. | Grover S et al. | — | 2013 | → |
| Probucol increases striatal glutathione peroxidase activity and protects against 3-nitropropionic acid-induced pro-oxidative damage in rats. | Colle D et al. | — | 2013 | → |
| Lipid lowering agents, cognitive decline, and dementia: the three-city study. | Ancelin ML et al. | — | 2012 | → |
| Neuroprotection in diabetic retinopathy. | Hernández C et al. | — | 2012 | → |
| The PPARα Agonist Fenofibrate Reduces Prepulse Inhibition Disruption in a Neurodevelopmental Model of Schizophrenia. | Rolland B et al. | — | 2012 | → |